Inactive Instrument

Lonza Group Ltd Share Price Other OTC

Equities

LZAGY

US54338V1017

Biotechnology & Medical Research

Financials

Sales 2024 * 6.64B 7.29B 581B Sales 2025 * 7.44B 8.17B 652B Capitalization 38.06B 41.79B 3,332B
Net income 2024 * 904M 992M 79.13B Net income 2025 * 1.11B 1.22B 97.51B EV / Sales 2024 * 6.06 x
Net Debt 2024 * 2.18B 2.39B 190B Net Debt 2025 * 2.47B 2.71B 216B EV / Sales 2025 * 5.44 x
P/E ratio 2024 *
42.7 x
P/E ratio 2025 *
34.2 x
Employees -
Yield 2024 *
0.85%
Yield 2025 *
0.98%
Free-Float 95.87%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Lonza Group Ltd

Managers TitleAgeSince
Chief Executive Officer 72 24/04/17
Director of Finance/CFO 52 30/11/21
Chief Operating Officer 55 31/07/22
Members of the board TitleAgeSince
Director/Board Member 63 15/04/14
Director/Board Member 66 15/04/14
Director/Board Member 58 04/05/22
More insiders
Lonza Group AG is one of the world leaders of the development, production and marketing of chemical products. Net sales break down by family of products and services as follows: - bio-pharmaceuticals (52.6%): exclusive syntheses, microbiological fermentation products , mammalian cell cultures, etc.; - capsules and dosing solutions for biopharmaceuticals, drugs and nutrition products (20.3%). In addition, the group offers nutritional ingredients; - small molecule drug substances (13.2%); - technologies and platforms for manufacturing processes and production of cell and gene therapies (11.1%); - other (2.8%). Net sales are distributed geographically as follows: Switzerland (16%), Europe (29.8%), the United States (38.8%), the Americas (3%), Japan (3.7%), China (2.6%), Asia (5.8%) and other (0.3%).
Calendar
More about the company